KaNDy Therapeutics
→
Bayer
Acquisition · Cash + milestone payments · announced Aug 11, 2020
Announced
Aug 11, 2020
Closed
Sep 9, 2020
Economics
Cash + milestone payments()
Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Bayer press release — KaNDy Therapeutics acquisition, 2020
$425M upfront; up to $450M in development milestones + triple-digit-million sales milestones
Target
KaNDy Therapeutics
Menopause · Clinical / therapeutic
HQ Stevenage, UK · Founded 2017
Clinical-stage biotech developing NT-814 (elinzanetant) for menopausal vasomotor symptoms
- Business Wire - Bayer acquisition announcement (August 11, 2020)
- Business Wire - Bayer completion announcement (September 9, 2020)
- Bayer.com media release
Acquirer
Bayer
Healthcare
HQ Leverkusen, Germany
Global pharma and life sciences company; leader in women's healthcare and contraception
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Reinforced Bayer's women's healthcare pipeline with NT-814/elinzanetant, a non-hormonal Phase IIb compound for moderate-to-severe menopausal vasomotor symptoms
Evidence ladder
Secondary (press / IR)
Business Wire press release (August 11, 2020)
Tertiary (trade / analyst)
Bayer.com media (September 9, 2020)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- $425M upfront; up to $450M in development milestones + triple-digit-million sales milestones
- Pre-deal valuation sourced from: Bayer press release — KaNDy Therapeutics acquisition, 2020. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Menopause
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| Ogeda SA | Astellas Pharma | Apr 3, 2017 | same evidence class |
Other verified deals by Bayer
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Bayer are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — KaNDy Therapeutics (Menopause). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.